- Conditions
- Healthy
- Interventions
- Poziotinib, Itraconazole, Phenytoin, Paroxetine
- Drug
- Lead sponsor
- Spectrum Pharmaceuticals, Inc
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 74 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1297–1320
of 17,839
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Advanced Cancers
- Interventions
- Azacitidine, Lenalidomide, Grifola Frondosa
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 13 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Small Cell Lung Cancer
- Interventions
- Olaparib, Temozolomide
- Drug
- Lead sponsor
- Zofia Piotrowska
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2023
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts
- Conditions
- Acute Lymphoblastic Leukemia
- Interventions
- inotuzumab ozogamicin, FLAG (fludarabine, cytarabine and G-CSF), HIDAC (high dose cytarabine), cytarabine and mitoxantrone
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 326 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 96
- States / cities
- La Jolla, California • Los Angeles, California • Orange, California + 39 more
- Conditions
- Macular Degeneration
- Interventions
- pazopanib eye drops, placebo, ranibizumab intravitreal injection
- Drug · Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 510 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 37
- States / cities
- Peoria, Arizona • Phoenix, Arizona • Tucson, Arizona + 31 more
- Conditions
- Melanoma, Non Small Cell Lung Cancer
- Interventions
- enoblituzumab plus ipilimumab
- Biological
- Lead sponsor
- MacroGenics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 10
- States / cities
- Los Angeles, California • New Haven, Connecticut • Miami Beach, Florida + 7 more
- Conditions
- Venous Thrombosis
- Interventions
- low dose intravenous heparin (LDIVH), Heparin
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 152 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2014
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- RSV (GSK3389245A) lower dose formulation vaccine, RSV (GSK3389245A) higher dose formulation vaccine, GSK's multicomponent meningococcal B vaccine, Pfizer's meningococcal group A, C, W-135 and Y conjugate vaccine, GSK's pneumococcal polysaccharide conjugate vaccine, GSK's meningococcal group A, C, W-135 and Y conjugate vaccine, Placebo
- Biological · Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 6 Months to 7 Months
- Enrollment
- 201 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2021
- U.S. locations
- 4
- States / cities
- Atlanta, Georgia • Nampa, Idaho • Louisville, Kentucky + 1 more
- Conditions
- Wound Healing
- Interventions
- GSK1278863, Placebo
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 65 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2017
- U.S. locations
- 7
- States / cities
- Castro Valley, California • Washington D.C., District of Columbia • Miami, Florida + 4 more
- Conditions
- Primary Immune Deficiency Disorder
- Interventions
- CUTAQUIG
- Drug
- Lead sponsor
- Octapharma
- Industry
- Eligibility
- 2 Years to 75 Years
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 18
- States / cities
- Scottsdale, Arizona • Irvine, California • Santa Barbara, California + 15 more
- Conditions
- HIV Infections
- Interventions
- Emtricitabine (FTC), Tenofovir Disoproxil Fumarate (TDF), Efavirenz (EFV), FTC/TDF, FTC/TDF/EFV, Lamivudine/zidovudine
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 517 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2009
- U.S. locations
- 5
- States / cities
- Beverly Hills, California • Washington D.C., District of Columbia • Orlando, Florida + 2 more
- Conditions
- Multiple Myeloma
- Interventions
- AT7519M, Bortezomib
- Drug
- Lead sponsor
- Astex Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 5
- States / cities
- Boston, Massachusetts • New York, New York • Milwaukee, Wisconsin
- Conditions
- Becker Muscular Dystrophy, Sporadic Inclusion Body Myositis
- Interventions
- rAAV1.CMV.huFollistatin344
- Biological
- Lead sponsor
- Nationwide Children's Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- AML/MDS, CD33 Expressing Hematological Malignancies, FLT3 Expressing Hematological Malignancies
- Interventions
- SENTI-202
- Biological
- Lead sponsor
- Senti Biosciences
- Industry
- Eligibility
- 18 Years to 74 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2040
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Denver, Colorado • Jacksonville, Florida + 3 more
- Conditions
- Indolent Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma
- Interventions
- Idelalisib, Rituximab, Bendamustine, Ofatumumab, Fludarabine, Everolimus, Bortezomib, Chlorambucil, Lenalidomide
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 241 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 11
- States / cities
- Huntsville, Alabama • Los Angeles, California • Palo Alto, California + 8 more
- Conditions
- Healthy
- Interventions
- PF-05212365
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2011
- U.S. locations
- 3
- States / cities
- New Haven, Connecticut
- Conditions
- Prostate Cancer, Prostate Adenocarcinoma
- Interventions
- Sunphenon, Placebo
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 115 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 2
- States / cities
- Tampa, Florida • Westwood, Kansas
- Conditions
- Acute Coronary Syndromes
- Interventions
- CER-001, Placebo
- Drug
- Lead sponsor
- Cerenis Therapeutics, SA
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 301 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 13
- States / cities
- Huntsville, Alabama • San Diego, California • Torrance, California + 9 more
- Conditions
- Newly Diagnosed, Previously Untreated Multiple Myeloma
- Interventions
- Lenalidomide, Dexamethasone, Elotuzumab
- Drug · Biological
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2020
- U.S. locations
- 9
- States / cities
- San Francisco, California • Hollywood, Florida • Peoria, Illinois + 6 more
- Conditions
- Toxicant Exposure, Firefighter, Occupational Exposure to Chemicals
- Interventions
- Colesevelam, Placebo
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Viral Infection
- Interventions
- UV-4B 30 mg oral solution, UV-4B 75 mg oral solution, UV-4B 150 mg oral solution, UV-4B X mg (dose to be determined) oral solution, UV-4B Y mg (dose to be determined) oral solution, Placebo
- Drug
- Lead sponsor
- Emergent BioSolutions
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 2
- States / cities
- Dallas, Texas • Madison, Wisconsin
- Conditions
- Metastatic Melanoma
- Interventions
- Aldesleukin: All Patients, Nivolumab: Cohort 1 (Cutaneous), Nivolumab: Cohort 2 (Ocular), Ipilimumab: Cohort 2 (Ocular)
- Drug
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Burnsville, Minnesota
- Conditions
- Schizophrenia
- Interventions
- Xanomeline and Trospium Chloride Capsules
- Drug
- Lead sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 152 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 34
- States / cities
- Bentonville, Arkansas • Little Rock, Arkansas • Anaheim, California + 27 more
- Conditions
- Hepatocellular Carcinoma, Advanced Cancer
- Interventions
- Sorafenib, CVM-1118
- Drug
- Lead sponsor
- TaiRx, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Charleston, South Carolina